美国植物来源原料药（API）市场规模、份额和趋势分析报告：按分子类型、最终用途和细分市场预测（2025-2033 年）

美国植物来源原料药市场概述

2024年美国植物来源原料药（API）市场规模估计为96.9亿美元，预计2033年将达到157.7亿美元。

预计2025年至2033年间，该市场将以5.5%的复合年增长率成长。天然且永续的药物成分日益普及，推动了市场强劲成长。消费者对草药和植物来源治疗方法的偏好不断增强，也带动了对合成添加剂更少、安全性更高的药物的需求。

製药公司正集中研发力量，致力于发现新的生物活性化合物并开发疗效较佳的製剂。萃取、纯化和分析技术的进步提高了植物来源原料药的产量、均一性和稳定性，从而生产出符合严格标准的高品质产品。例如，2025年9月，《分子生物学最新进展》（Current Issues in Molecular Biology）报告称，代谢工程已将Terpenoids（包括紫杉醇）的产量提高了25倍，青蒿素的产量提高了38%。多组体学方法和CRISPR技术解决了天然产物产量低和规模化生产难题，为从实验室规模生产向工业化生产过渡铺平了道路。这些创新正在推动植物来源药物成分（API）广泛应用于主流药物，拓展治疗选择，并增强消费者信心。

技术进步是市场扩张的关键驱动力。植物组织培养、酵素辅助萃取和生物修復等技术能够在维持疗效的同时，实现高品质原料药的规模化生产。包括层析法和光谱的先进分析技术，能够确保生物活性化合物的准确鑑定和定量，并降低生产过程中的变异性。这些改进提升了产品质量，优化了生产成本，并支持了大规模商业化。整合生物技术和传统植物萃取技术的生产平台能够实现高效稳定的生产。这些进步正在吸引新的市场参与企业，并鼓励现有公司拓展其植物来源产品系列。技术和製程的持续创新提升了植物来源原料药的潜力，从而能够发现用于多种治疗应用的新型化合物。

美国慢性病和文明病的日益普遍，进一步推动了对植物来源药物成分（API）的需求。植物植物来源化合物正越来越多地被用于治疗心血管疾病、糖尿病、发炎和神经退化性疾病等。製药公司与研究机构之间的合作正在加速新分子的发现，并支持有效治疗方法的开发。例如，2025年3月，学术期刊《天然产物与生物勘探》（Natural Products and Bioprospecting）报告了从曲霉属真菌中分离出217种新型Terpenoids，显示真菌是抗菌化合物的未开发来源。人们对补充和整合医学日益增长的兴趣也为市场扩张提供了更多机会。儘管正在进行的临床研究已证实了其疗效和安全性，但製造商正利用这些发现来开发创新剂型，这将推动美国植物来源原料药市场在未来十年内保持强劲且持续的成长。

目录

第一章调查方法和范围

第二章执行摘要

第三章美国植物来源原料药市场变数、趋势与范围

• 市场谱系展望
• 市场动态
• 商业环境分析
  • 产业分析—波特五力分析
  • PESTLE分析
  • 管道分析
  • 专利到期分析
  • 定价分析

第四章美国植物来源原料药市场：依分子类型分類的商业分析

• 按分子类型分類的市场份额（2024 年和 2033 年）
• 按分子类型分類的市场规模、预测和趋势分析（2021-2033 年）
• 生物碱
• 花青素
• 黄酮类化合物
• 酚酸
• Terpenoids
• 木质素和芪
• 其他的

第五章美国植物来源原料药市场：依最终用途分類的业务分析

• 按最终用途分類的市场份额（2024 年和 2033 年）
• 市场规模、预测与趋势分析（按应用领域划分，2021-2033 年）
• 製药
• 营养补充品
• 草药产业
• 其他的

第六章 竞争情势

• 参与公司概况
• 企业市场分析
• 公司分类
• 策略规划
• 公司简介/列表
  • Brains Bioceutical Corp.
  • Arboris LLC
  • Cargill, Incorporated
  • Roquette
  • HimPharm
  • Kothari Phytochemicals &Industries Ltd.
  • BASF
  • Evonik Industries
  • Alchem International
  • Sami-Sabinsa Group

U.S. Plant-based API Market Summary

The U.S. plant-based API market size was estimated at USD 9.69 billion in 2024 and is projected to reach USD 15.77 billion by 2033, growing at a CAGR of 5.5% from 2025 to 2033. The market is witnessing strong growth due to the increasing adoption of natural and sustainable pharmaceutical ingredients. Rising consumer preference for herbal and plant-derived therapies drives demand for medications with fewer synthetic additives and improved safety profiles.

Pharmaceutical companies are focusing on research to identify new bioactive compounds and develop formulations with enhanced efficacy. Advances in extraction, purification, and analytical technologies have improved the yield, consistency, and stability of plant-based APIs, yielding high-quality products that meet stringent standards. For instance, in September 2025, Current Issues in Molecular Biology reported that metabolic engineering raised terpenoid production, including paclitaxel, by 25 fold and enhanced artemisinin yield by 38%. Multi-omics approaches and CRISPR tools addressed low natural yields and scale-up challenges, providing a roadmap for translating lab-scale production into industrial manufacturing. These innovations support broader integration of plant-based APIs in mainstream pharmaceuticals, expanding therapeutic options and strengthening consumer confidence.

Technological advancements are a major factor in market expansion. Methods such as plant tissue culture, enzyme-assisted extraction, and biorementation enable the scalable production of high-quality APIs while maintaining therapeutic effectiveness. Sophisticated analytical techniques, including chromatography and spectroscopy, ensure precise identification and quantification of bioactive compounds, reducing variability in manufacturing. These improvements enhance product quality and optimize production costs, supporting large-scale commercialization. Integrated production platforms combining biotechnology with traditional plant extraction enable efficient and consistent manufacturing. Such progress attracts new players to the market and encourages established companies to expand their plant-based product portfolios. Continuous innovation in technology and processing enhances the potential of plant-based APIs, enabling the discovery of novel compounds for diverse therapeutic applications.

Rising prevalence of chronic and lifestyle-related diseases in the U.S. further fuels demand for plant-based APIs. Conditions such as cardiovascular disorders, diabetes, inflammation, and neurodegenerative diseases are increasingly addressed using plant-derived compounds due to their targeted therapeutic benefits. Collaborations between pharmaceutical firms and research institutions accelerate the discovery of novel molecules and support the development of effective treatments. For instance, in March 2025, Natural Products and Bioprospecting reported the isolation of 217 new terpenoids from Aspergillus species, highlighting fungi as an under-exploited source of antimicrobial compounds. The growing interest in complementary and integrative medicine presents additional opportunities for market expansion. Continuous clinical studies validate efficacy and safety, while manufacturers leverage these insights to develop innovative dosage forms, ensuring strong and sustained growth for the U.S. plant-based API market over the coming decade.

U.S. Plant-based API Market Report Segmentation

This report forecasts revenue growth at the country level and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the U.S. plant-based API market report based on molecule type and end use:

• Molecule Type Outlook (Revenue, USD Million, 2021 - 2033)
• Alkaloids
• Anthocyanin
• Flavonoids
• Phenolic Acids
• Terpenoids
• Lignin and Stilbenes
• Others
• End Use Outlook (Revenue, USD Million, 2021 - 2033)
• Pharmaceuticals
• Nutraceuticals
• Herbal Based Industries
• Others

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Molecule Type
  • 1.2.2. End Use
• 1.3. Estimates and Forecast Timeline
• 1.4. Research Methodology
• 1.5. Information Procurement
  • 1.5.1. Purchased Database
  • 1.5.2. GVR's Internal Database
  • 1.5.3. Secondary Sources
  • 1.5.4. Primary Research
• 1.6. Information Analysis
  • 1.6.1. Data Analysis Models
• 1.7. Market Formulation & Data Visualization
• 1.8. Model Details
  • 1.8.1. Commodity Flow Analysis
• 1.9. List of Secondary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Snapshot
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. U.S. Plant-based API Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
  • 3.2.2. Market Restraint Analysis
• 3.3. Business Environment Analysis
  • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
    • 3.3.1.1. Supplier Power
    • 3.3.1.2. Buyer Power
    • 3.3.1.3. Substitution Threat
    • 3.3.1.4. Threat of New Entrants
    • 3.3.1.5. Competitive Rivalry
  • 3.3.2. PESTLE Analysis
  • 3.3.3. Pipeline Analysis
  • 3.3.4. Patent Expiry Analysis
  • 3.3.5. Pricing Analysis

Chapter 4. U.S. Plant-based API Market: Molecule Type Business Analysis

• 4.1. Molecule Type Market Share, 2024 & 2033
• 4.2. Molecule Type Segment Dashboard
• 4.3. Market Size & Forecasts and Trend Analysis, by Molecule Type, 2021 to 2033 (USD Million)
• 4.4. Alkaloids
  • 4.4.1. Alkaloids Market, 2021 - 2033 (USD Million)
• 4.5. Anthocyanin
  • 4.5.1. Anthocyanin Market, 2021 - 2033 (USD Million)
• 4.6. Flavonoids
  • 4.6.1. Flavonoids Market, 2021 - 2033 (USD Million)
• 4.7. Phenolic Acids
  • 4.7.1. Phenolic Acids Market, 2021 - 2033 (USD Million)
• 4.8. Terpenoids
  • 4.8.1. Terpenoids Market, 2021 - 2033 (USD Million)
• 4.9. Lignin and Stilbenes
  • 4.9.1. Lignin and Stilbenes Market, 2021 - 2033 (USD Million)
• 4.10. Others
  • 4.10.1. Others Market, 2021 - 2033 (USD Million)

Chapter 5. U.S. Plant-based API Market: End Use Business Analysis

• 5.1. End Use Market Share, 2024 & 2033
• 5.2. End Use Segment Dashboard
• 5.3. Market Size & Forecasts and Trend Analysis, by end use, 2021 to 2033 (USD Million)
• 5.4. Pharmaceuticals
  • 5.4.1. Pharmaceuticals Market, 2021 - 2033 (USD Million)
• 5.5. Nutraceuticals
  • 5.5.1. Nutraceuticals Market, 2021 - 2033 (USD Million)
• 5.6. Herbal Based Industries
  • 5.6.1. Herbal Based Industries Market, 2021 - 2033 (USD Million)
• 5.7. Others
  • 5.7.1. Others Market, 2021 - 2033 (USD Million)

Chapter 6. Competitive Landscape

• 6.1. Participant Overview
• 6.2. Company Market Position Analysis
• 6.3. Company Categorization
• 6.4. Strategy Mapping
• 6.5. Company Profiles/Listing
  • 6.5.1. Brains Bioceutical Corp.
    • 6.5.1.1. Overview
    • 6.5.1.2. Financial Performance
    • 6.5.1.3. Product Benchmarking
    • 6.5.1.4. Strategic Initiatives
  • 6.5.2. Arboris LLC
    • 6.5.2.1. Overview
    • 6.5.2.2. Financial Performance
    • 6.5.2.3. Product Benchmarking
    • 6.5.2.4. Strategic Initiatives
  • 6.5.3. Cargill, Incorporated
    • 6.5.3.1. Overview
    • 6.5.3.2. Financial Performance
    • 6.5.3.3. Product Benchmarking
    • 6.5.3.4. Strategic Initiatives
  • 6.5.4. Roquette
    • 6.5.4.1. Overview
    • 6.5.4.2. Financial Performance
    • 6.5.4.3. Product Benchmarking
    • 6.5.4.4. Strategic Initiatives
  • 6.5.5. HimPharm
    • 6.5.5.1. Overview
    • 6.5.5.2. Financial Performance
    • 6.5.5.3. Product Benchmarking
    • 6.5.5.4. Strategic Initiatives
  • 6.5.6. Kothari Phytochemicals & Industries Ltd.
    • 6.5.6.1. Overview
    • 6.5.6.2. Financial Performance
    • 6.5.6.3. Product Benchmarking
    • 6.5.6.4. Strategic Initiatives
  • 6.5.7. BASF
    • 6.5.7.1. Overview
    • 6.5.7.2. Financial Performance
    • 6.5.7.3. Product Benchmarking
    • 6.5.7.4. Strategic Initiatives
  • 6.5.8. Evonik Industries
    • 6.5.8.1. Overview
    • 6.5.8.2. Financial Performance
    • 6.5.8.3. Product Benchmarking
    • 6.5.8.4. Strategic Initiatives
  • 6.5.9. Alchem International
    • 6.5.9.1. Overview
    • 6.5.9.2. Financial Performance
    • 6.5.9.3. Product Benchmarking
    • 6.5.9.4. Strategic Initiatives
  • 6.5.10. Sami-Sabinsa Group
    • 6.5.10.1. Overview
    • 6.5.10.2. Financial Performance
    • 6.5.10.3. Product Benchmarking
    • 6.5.10.4. Strategic Initiatives

List of Tables

• Table 1 List of secondary sources
• Table 2 List of abbreviations
• Table 3 US plant-based API market, by molecule type, 2021 - 2033 (USD Million)
• Table 4 US plant-based API market, by end use, 2021 - 2033 (USD Million)

List of Figures

• Fig. 1 U.S. Plant-based API market segmentation
• Fig. 2 Market research process
• Fig. 3 Data triangulation techniques
• Fig. 4 Primary research pattern
• Fig. 5 Market research approaches
• Fig. 6 Value-chain-based sizing & forecasting
• Fig. 7 Market formulation & validation
• Fig. 8 Market snapshot
• Fig. 9 Competitive landscape
• Fig. 10 U.S. Plant-based API market dynamics
• Fig. 11 U.S. Plant-based API market: Porter's five forces analysis
• Fig. 12 U.S. Plant-based API market: PESTLE analysis
• Fig. 13 Molecule Type market, 2021 - 2033 (USD Million)
• Fig. 14 Alkaloids market, 2021 - 2033 (USD Million)
• Fig. 15 Anthocyanin market, 2021 - 2033 (USD Million)
• Fig. 16 Flavonoids market, 2021 - 2033 (USD Million)
• Fig. 17 Phenolic Acids market, 2021 - 2033 (USD Million)
• Fig. 18 Terpenoids market, 2021 - 2033 (USD Million)
• Fig. 19 Lignin and Stilbenes market, 2021 - 2033 (USD Million)
• Fig. 20 Others market, 2021 - 2033 (USD Million)
• Fig. 21 End use market, 2021 - 2033 (USD Million)
• Fig. 22 Pharmaceuticals market, 2021 - 2033 (USD Million)
• Fig. 23 Nutraceuticals market, 2021 - 2033 (USD Million)
• Fig. 24 Herbal Based Industries market, 2021 - 2033 (USD Million)
• Fig. 25 Others market, 2021 - 2033 (USD Million)
• Fig. 26 Company categorization
• Fig. 27 Company market position analysis
• Fig. 28 Strategic framework